204 related articles for article (PubMed ID: 20004576)
1. Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket.
Stewart KD; Huth JR; Ng TI; McDaniel K; Hutchinson RN; Stoll VS; Mendoza RR; Matayoshi ED; Carrick R; Mo H; Severin J; Walter K; Richardson PL; Barrett LW; Meadows R; Anderson S; Kohlbrenner W; Maring C; Kempf DJ; Molla A; Olejniczak ET
Bioorg Med Chem Lett; 2010 Jan; 20(2):612-7. PubMed ID: 20004576
[TBL] [Abstract][Full Text] [Related]
2. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements.
Ferrer M; Kapoor TM; Strassmaier T; Weissenhorn W; Skehel JJ; Oprian D; Schreiber SL; Wiley DC; Harrison SC
Nat Struct Biol; 1999 Oct; 6(10):953-60. PubMed ID: 10504731
[TBL] [Abstract][Full Text] [Related]
3. A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency.
Nomura W; Hashimoto C; Ohya A; Miyauchi K; Urano E; Tanaka T; Narumi T; Nakahara T; Komano JA; Yamamoto N; Tamamura H
ChemMedChem; 2012 Feb; 7(2):205-8. PubMed ID: 22247043
[No Abstract] [Full Text] [Related]
4. [The current progress in the development of HIV-1 fusion inhibitors].
Shi WG; Jia QY; Liu KL
Yao Xue Xue Bao; 2010 Feb; 45(2):184-93. PubMed ID: 21351428
[TBL] [Abstract][Full Text] [Related]
5. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.
Bianchi E; Finotto M; Ingallinella P; Hrin R; Carella AV; Hou XS; Schleif WA; Miller MD; Geleziunas R; Pessi A
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12903-8. PubMed ID: 16129831
[TBL] [Abstract][Full Text] [Related]
6. Peptide and non-peptide HIV fusion inhibitors.
Jiang S; Zhao Q; Debnath AK
Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
[TBL] [Abstract][Full Text] [Related]
7. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
Champagne K; Shishido A; Root MJ
J Biol Chem; 2009 Feb; 284(6):3619-27. PubMed ID: 19073602
[TBL] [Abstract][Full Text] [Related]
8. Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection.
Lai W; Wang C; Yan J; Liu H; Zhang W; Lin B; Xi Z
Bioorg Med Chem; 2020 Feb; 28(4):115214. PubMed ID: 31932193
[TBL] [Abstract][Full Text] [Related]
9. Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity.
Oishi S; Ito S; Nishikawa H; Watanabe K; Tanaka M; Ohno H; Izumi K; Sakagami Y; Kodama E; Matsuoka M; Fujii N
J Med Chem; 2008 Feb; 51(3):388-91. PubMed ID: 18197613
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41.
Wang Y; Lu H; Zhu Q; Jiang S; Liao Y
Bioorg Med Chem Lett; 2010 Jan; 20(1):189-92. PubMed ID: 19932616
[TBL] [Abstract][Full Text] [Related]
11. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M
Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053
[TBL] [Abstract][Full Text] [Related]
12. HIV entry inhibitors: progress in development and application.
Lai WH; Huang L; Chen CH
Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
[TBL] [Abstract][Full Text] [Related]
13. Putative role of membranes in the HIV fusion inhibitor enfuvirtide mode of action at the molecular level.
Veiga S; Henriques S; Santos NC; Castanho M
Biochem J; 2004 Jan; 377(Pt 1):107-10. PubMed ID: 14514352
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of HIV-1 attachment. Part 3: A preliminary survey of the effect of structural variation of the benzamide moiety on antiviral activity.
Meanwell NA; Wallace OB; Wang H; Deshpande M; Pearce BC; Trehan A; Yeung KS; Qiu Z; Wright JJ; Robinson BA; Gong YF; Wang HG; Spicer TP; Blair WS; Shi PY; Lin PF
Bioorg Med Chem Lett; 2009 Sep; 19(17):5136-9. PubMed ID: 19632112
[TBL] [Abstract][Full Text] [Related]
15. Small molecule fusion inhibitors: design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41.
He XY; Lu L; Qiu J; Zou P; Yu F; Jiang XK; Li L; Jiang S; Liu S; Xie L
Bioorg Med Chem; 2013 Dec; 21(23):7539-48. PubMed ID: 23673219
[TBL] [Abstract][Full Text] [Related]
16. The N-Terminal T-T Motif of a Third-Generation HIV-1 Fusion Inhibitor Is Not Required for Binding Affinity and Antiviral Activity.
Chong H; Qiu Z; Su Y; He Y
J Med Chem; 2015 Aug; 58(16):6378-88. PubMed ID: 26256053
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.
Lawless MK; Barney S; Guthrie KI; Bucy TB; Petteway SR; Merutka G
Biochemistry; 1996 Oct; 35(42):13697-708. PubMed ID: 8885850
[TBL] [Abstract][Full Text] [Related]
18. A multi-functional peptide as an HIV-1 entry inhibitor based on self-concentration, recognition, and covalent attachment.
Zhao L; Tong P; Chen YX; Hu ZW; Wang K; Zhang YN; Zhao DS; Cai LF; Liu KL; Zhao YF; Li YM
Org Biomol Chem; 2012 Aug; 10(32):6512-20. PubMed ID: 22760295
[TBL] [Abstract][Full Text] [Related]
19. A novel enzyme-linked immunosorbent assay for screening HIV-1 fusion inhibitors targeting HIV-1 Gp41 core structure.
Pang W; Wang RR; Gao YD; Yang LM; Sun Y; Huang JF; Tien P; Zheng YT
J Biomol Screen; 2011 Feb; 16(2):221-9. PubMed ID: 21297108
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 gp41: mediator of fusion and target for inhibition.
Weiss CD
AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]